A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5)

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Wolfgang R SperrPeter Valent

Abstract

High-dose intermittent cytarabine is an effective postremission treatment for patients with acute myeloid leukemia (AML). This regimen is a safe approach in patients < 60 years but produced severe neurotoxicity in the elderly. We have established a dose-reduced age-adapted consolidation using intermediate dose (IDAC; 2 x 1 g/m(2) i.v., days 1, 3, and 5) for AML patients >/= 60 years. Forty-seven de novo AML patients in complete remission (CR; median age, 70 years) were scheduled to receive four consolidation cycles of IDAC. In 25 of 47 patients (53%), all four cycles were administered: 9 (19%) received three cycles; 7 (15%) received two cycles; and 6 patients (12%) one cycle. Treatment was well tolerated without neurotoxicity. The median number of days with severe neutropenia (absolute neutrophil count < 500/microl) was 9. Neutropenic fever occurred in 22 of 47 patients (49%) during the first cycle, in 24 of 41 (60%) during the second, in 15 of 34 (44%) during the third, and in 18 of 25 (72%) during the fourth cycle. Only 1 patient died during consolidation (cardiac failure). The median overall survival, disease-free survival, and continuous CR were 10.6, 15.5, and 15.9 months, respectively. The probability of overall survival,...Continue Reading

References

Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
Feb 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H TillyL Degos
Apr 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A CassilethM J O'Connell
Dec 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T BüchnerG Zeile
Jan 1, 1994·British Journal of Haematology·M BaudardR Zittoun
Mar 1, 1996·Baillière's Clinical Haematology·B Löwenberg
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W HiddemannT Büchner
May 18, 2001·Best Practice & Research. Clinical Haematology·T BüchnerA Heinecke
Aug 14, 2001·Critical Reviews in Oncology/hematology·A PintoF Ferrara
Jun 13, 2002·Reviews in Clinical and Experimental Hematology·Thomas BüchnerUNKNOWN German AML Co-Operative Group
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards

❮ Previous
Next ❯

Citations

Apr 1, 2006·Annals of Hematology·Je-Hwan LeeUNKNOWN Cooperative Study Group A for Hematology
Nov 28, 2006·Leukemia Research·Andrea ZatkovaPeter Valent
Jun 3, 2017·Leukemia & Lymphoma·Jonathan A Webster, Keith W Pratz
Sep 28, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arnaud PigneuxUNKNOWN French Innovative Leukemia Organization
Jan 21, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Maria-T KrauthPeter Valent
Jul 15, 2018·Wiener klinische Wochenschrift·Peter ValentChristoph Zielinski
Jan 5, 2021·Current Opinion in Hematology·Rory M Shallis, Nikolai A Podoltsev
Oct 6, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Wenhui LiTimothy Kubal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.